Parkman Healthcare Expands Stake in InspireMD Backing Carotid Innovation

InspireMD, Inc. (NASDAQ:NSPR) is among the  best fundamentally strong penny stocks to buy right now. According to the latest filing with the SEC, Parkman Healthcare Partners LLC has increased its position in InspireMD, Inc. (NASDAQ:NSPR) by 37.1% during the first quarter. Following the purchase of 316,700 shares, the institutional investor now owns 1,171,416 shares of the company’s stock, which translates to an ownership of nearly 3.82%.

Powered by a clear procedure-agnostic strategy, InspireMD, Inc. (NASDAQ:NSPR) is the first company to invest in the broadest toolkit of carotid procedures, strengthening not only carotid artery stenting, commonly known as CAS, but also transcarotid artery revascularization, known as TCAR.

The company’s ongoing hiring plans aren’t something hidden. With a stellar team of sales and clinical support specialists, InspireMD, Inc. (NASDAQ:NSPR) has already begun to see its engagement enhanced and market position strengthened. A testament to this is the company’s recent appointment of Mike Lawless as the new CFO, who brings decades of financial stewardship and a strong commitment to InspireMD’s mission.

InspireMD, Inc. (NASDAQ:NSPR) is a Florida-based medical device company that develops and commercializes treatments for carotid artery and other vascular diseases. The company provides various systems like CGuard carotid embolic prevention system and SwitchGuard neuroprotection system.

While we acknowledge the potential of NSPR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.